logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Glioma Immunotherapeutic Approaches 1st Edition Tomotoshi Marumoto

  • SKU: BELL-4392666
Glioma Immunotherapeutic Approaches 1st Edition Tomotoshi Marumoto
$ 31.00 $ 45.00 (-31%)

4.3

38 reviews

Glioma Immunotherapeutic Approaches 1st Edition Tomotoshi Marumoto instant download after payment.

Publisher: Springer-Verlag New York
File Extension: PDF
File size: 2.4 MB
Pages: 226
Author: Tomotoshi Marumoto, Hideyuki Saya (auth.), Ryuya Yamanaka MD, PhD (eds.)
ISBN: 9781461431459, 9781461431466, 146143145X, 1461431468
Language: English
Year: 2012
Edition: 1

Product desciption

Glioma Immunotherapeutic Approaches 1st Edition Tomotoshi Marumoto by Tomotoshi Marumoto, Hideyuki Saya (auth.), Ryuya Yamanaka Md, Phd (eds.) 9781461431459, 9781461431466, 146143145X, 1461431468 instant download after payment.

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.

Related Products